NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
BeOne Medicines
BeOne Medicines
Novartis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Samsung Medical Center
RemeGen Co., Ltd.
BeOne Medicines
Second Affiliated Hospital of Nanchang University
Indaptus Therapeutics, Inc
Fujian Cancer Hospital
Sichuan University